계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
ARCH Venture Partners
About
ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
- Chicago,Illinois,United States
- http://www.archventure.com
Details
- Industries
- Finance,Financial Services,Venture Capital
- Founded date
- Jan 1, 1986
- Operating Status
- Active
- Investor Type
- Venture Capital
ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.ARCH has raised ten venture funds totaling over $3 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors.
Funds Raised
| Announced Date | Fund Name | Money Raised | |
|---|---|---|---|
| Jun 29, 2022 | Arch Venture Fund XII | $3B | |
| Jan 28, 2021 | Arch Venture Fund XI | $1.85B | |
| Oct 25, 2019 | ARCH Venture Fund X | $635.75M | |
| Nov 21, 2016 | ARCH Venture Fund IX | $408.38M | |
| Aug 27, 2014 | ARCH Venture Fund VIII | $400M |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jan 5, 2023
Psioxus Therapeutics
|
Debt Financing | $30M | Biotechnology | Yes |
|
Dec 19, 2022
Protillion Biosciences
|
Series A | $18M | Biopharma | Yes |
|
Dec 16, 2022
Synchron
|
Series C | $75M | Computer | Yes |
|
Dec 15, 2022
Synchron
|
Series C | $75M | Computer | Yes |
|
Dec 5, 2022
SonoThera
|
Series A | $60.75M | Biopharma | Yes |
Employee Profiles
Exits
ARCH Venture Partners has had 100 exits. ARCH Venture Partners most notable exits include Prime Medicine , EQRx
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Oct 20, 2022 | Prime Medicine | IPO | Biotechnology | Detail |
| Dec 17, 2021 | EQRx | IPO | Biotechnology | Detail |
| Sep 29, 2021 | Transcenta | IPO | Biopharma | Detail |
| Aug 16, 2021 | Genuity Science | M&A | Analytics | Detail |
| Aug 11, 2021 | Nebula Genomics | M&A | Biotechnology | Detail |
